Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs
Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Orient Pharma Co., Ltd.
Collaborators:
National Defense Medical Center, Taiwan National Research Program for Biopharmaceuticals, Taiwan National Research Program for Biopharmaceutics, Taiwan